- Global Pharma News & Resources

Mitochondrial Disorders Treatment Market Sizing by Industry Share, Key Trends, Technique, Application, Worldwide Analysis by Top Leaders and Regional Forecast to 2026

SEATTLE, March 29, 2021, (PHARMIWEB) — Mitochondrial disorders are inherited chronic disorders that are characterized by a wide range of biochemical and genetic mitochondrial defects and mutations. This disorder affects multiple organs such as brain, heart, liver, skeletal muscles, kidney, and respiratory systems. Moreover, patients with mitochondrial disorders often suffer from muscle weakness, exercise intolerance, and fatigue due to reduction in mitochondrial respiration, which is caused due to mitochondrial DNA mutations leading to reduced ability to produce cellular adenosine triphosphate (ATP). Currently there are no effective treatments for the disease. The treatment of mitochondrial disorders is mostly performed with different vitamins, co-factors, off-label drugs approved for other indications, and nutritional supplements. However, research organizations and pharmaceutical companies are involved in development of novel drugs with technology advancements including the use of biomarkers, replacement therapies and sophisticated trial designs, thus creating a lucrative opportunity for the market growth.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@

Mitochondrial Disorders Treatment Market: Market Dynamics

Increasing prevalence of mitochondrial disorders resulting in significant morbidity and mortality combined with the higher potential of genetic transmission to the next generation are the factors that are expected to drive the market growth. For instance, according to the Wellcome Trust Center for Mitochondrial Research, 2015, around10 people per 100,000 have mitochondrial disorders, which is often expressed first in early childhood. Moreover, according to the Genetic and Rare Disease Information Center, women with mitochondrial genetic disorders have 50% chance with each pregnancy of passing along the altered gene to the offspring, thus indicating the rising burden of the disease. Furthermore, the mitochondrial disorders treatment market is expected to gain significant traction over the forecast period, as the pharmaceutical drugs approved for the treatment of primary mitochondrial disease have orphan drug status, thereby having a greater potential for market approval than conventional pharmaceuticals. Moreover, approval of novel drug molecules from the regulatory agencies is expected to create a lucrative opportunity for the growth of mitochondrial disorders treatment market. For instance, in April 2018, NeuroVive Pharmaceutical AB received orphan drug designation to KL1333 by the US Food and Drug administration (FDA) for the treatment of inherited mitochondrial respiratory chain diseases (MRCD).

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations

Apply Promo Code “CMIFIRST1000” and Get Up to 30% Discount
Buy-Now this Research Report @

Moreover, presence of various clinical trials undertaken by various research institutes to address the unmet need of the patients suffering with the mitochondrial disorders is expected to augment the market growth over the forecast period. For instance, in April, 2018, GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced results from the REVERSE Phase III clinical trial evaluating the safety and efficacy of a single intravitreal injection of GS010 (rAAV2/2-ND4) in for treating a mitochondrial disease- Leber Hereditary Optic Neuropathy (LHON).

Higher investments by the organizations in research and development supporting the researchers for the development of efficient therapies to address the unmet medical needs of the patients is expected to upsurge the growth of mitochondrial disorders treatment market over the forecast period. For instance, the Foundation for Mitochondrial Medicine (FMM) supports and accelerates the development for most promising mitochondrial research and treatments to treat various forms of mitochondrial disease and disorders by funding targeted therapeutic discovery project. In 2014, (FMM) entered into a collaboration with the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support a research project at the Department of Neuroscience at Mayo Clinic for investigating a mitochondria-targeted therapeutic approach to treating Parkinson’s disease. Moreover, United Mitochondria Disease Foundation (UMDF) along with the National Institute of Child Health and Human Development (NICHD) launched the Mitochondrial Disease Sequence Data Resource (MSeqDR) Consortium. The goals of this consortium is to facilitate deposition, curation, annotation, and integrated analysis of genomic data for mitochondrial diseases for clinical and research communities.

However, higher R&D cost, stringent regulations for the approval of novel therapies, lack of awareness and understanding of the disease are the factors that are expected to restrain the market growth.

Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @

Mitochondrial Disorders Treatment Market: Regional Dynamics

Regional segmentation of the global mitochondrial disorders treatment market by Coherent Market Insights include North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global mitochondrial disorders treatment market over the forecast period, owing to increasing prevalence of the disease and the rising number of initiatives to spread awareness and support novel drug development. For instance, according to the Institute of Medicine, U.S., 2015, around 30,000 U.S. population suffered from inherited defects in their mitochondria. Moreover, according to the Foundation for Mitochondrial Medicine, around 1,000 children per year are born with some form of mitochondrial disease in the U.S. Furthermore, the North American Mitochondrial Disease Consortium (NAMDC), a part of Rare Disease Clinical Research Network (RDCRN), specially works towards collecting information from mitochondrial disease patients in a clinical patient registry, thereby helping researchers to identify and recruit patients for future studies.

Mitochondrial Disorders Treatment Market: Competitive Landscape

Key players operating in the market are focused on adopting strategic collaborations with research organizations to advance drugs for rare diseases through clinical development. For instance, in February 2018, NeuroVive Pharmaceutical AB entered into collaboration with Karolinska Institute to develop a compound NV556 to treat patients with mitochondrial myopathy. The company is expected to initiate the clinical trials for the compound with the effective outcomes from its pre-clinical study.

To understand Research Methodology, please click

Key players operating in the global mitochondrial disorders treatment market include Centogene AG, GeneDx, Ixchel Pharma, Khondrion BV, Mitobridge, NeuroVive Pharmaceutical AB, Reata Pharmaceuticals Inc., and Stealth Biotherapeutics.

Mitochondrial Disorders Treatment Market: Market Taxonomy

On the basis of therapy type, the global mitochondrial disorders treatment market is segmented into:

  • Dietary Therapy
  • Vitamin and Supplement Therapy
  • Pipeline Therapies
    • NV556
    • KL1333
    • Others

On the basis of distribution channel, the global mitochondrial disorders treatment market is segmented into:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

On the basis of region, the global mitochondrial disorders treatment market is segmented into:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Table of Content

Global Mitochondrial Disorders Treatment Market Research Report
Section 1: Global Mitochondrial Disorders Treatment Industry Overview
Section 2: Global Economic Impact on Mitochondrial Disorders Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Mitochondrial Disorders Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Mitochondrial Disorders Treatment Market Forecast

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 29-Mar-2021